{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:44:06Z","timestamp":1793781846341,"version":"4.6.1"},"reference-count":168,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,10,22]],"date-time":"2027-10-22T00:00:00Z","timestamp":1824163200000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA210964"],"award-info":[{"award-number":["P50 CA210964"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA275065"],"award-info":[{"award-number":["U01 CA275065"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["0074956"],"award-info":[{"award-number":["0074956"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["0085704"],"award-info":[{"award-number":["0085704"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["0058419"],"award-info":[{"award-number":["0058419"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["R325-A19079"],"award-info":[{"award-number":["R325-A19079"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["R368-A21455"],"award-info":[{"award-number":["R368-A21455"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008273","name":"\u00d8jenfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008392","name":"Independent Research Fund Denmark Health and Disease","doi-asserted-by":"publisher","award":["1030-00070B"],"award-info":[{"award-number":["1030-00070B"]}],"id":[{"id":"10.13039\/100008392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1053\/j.gastro.2026.06.019","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T04:44:05Z","timestamp":1783917845000},"page":"798-816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular Subtypes of Cholangiocarcinoma and Their Translational Implications"],"prefix":"10.1053","volume":"171","author":[{"given":"Chiara","family":"Braconi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm J.","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper B.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis R.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2026.06.019_bib1","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in Western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib2","article-title":"Epidemiology of cholangiocarcinoma","author":"Qurashi","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib3","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3390\/cancers16152720","article-title":"Incidence and long-term outcomes of biliary tract cancers in Olmsted County, Minnesota from 1976 to 2018","volume":"16","author":"Nwankwo","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.gastro.2026.06.019_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41416-022-01824-4","article-title":"Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary","volume":"127","author":"Conway","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1053\/j.gastro.2026.06.019_bib5","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1016\/j.cgh.2025.12.013","article-title":"Rising intrahepatic cholangiocarcinoma rates in the United States are driving liver cancer rates in females","volume":"24","author":"Alvarez","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/toxics9060128","article-title":"Role of macrophages in cytotoxicity, reactive oxygen species production and DNA damage in 1,2-dichloropropane-exposed human cholangiocytes in vitro","volume":"9","author":"Ekuban","year":"2021","journal-title":"Toxics"},{"key":"10.1053\/j.gastro.2026.06.019_bib8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/oemed-2015-103427","article-title":"Relationship between cumulative exposure to 1,2-dichloropropane and incidence risk of cholangiocarcinoma among offset printing workers","volume":"73","author":"Kumagai","year":"2016","journal-title":"Occup Environ Med"},{"key":"10.1053\/j.gastro.2026.06.019_bib9","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.31557\/APJCP.2022.23.6.1837","article-title":"Cholangiocarcinoma attributed to occupation: a systematic reviews","volume":"23","author":"Seeherunwong","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1053\/j.gastro.2026.06.019_bib10","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001699","article-title":"Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses","author":"Han","year":"2026","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.06.019_bib11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1055-9965.EPI-20-1322","article-title":"Aspirin, statins, non-aspirin NSAIDs, metformin, and the risk of biliary cancer: a Swedish population-based cohort study","volume":"31","author":"Marcano-Bonilla","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.gastro.2026.06.019_bib12","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1016\/j.dld.2025.09.025","article-title":"Pancreatic cancer and biliary tract tumors in individuals with lynch syndrome","volume":"57","author":"Bujanda","year":"2025","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.gastro.2026.06.019_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejca.2022.08.032","article-title":"Age trends in biliary tract cancer incidence by anatomical subtype: a Swedish cohort study","volume":"175","author":"Rahman","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.gastro.2026.06.019_bib14","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/1055-9965.EPI-23-0388","article-title":"Independent of primary sclerosing cholangitis and cirrhosis, early adulthood obesity is associated with cholangiocarcinoma","volume":"32","author":"Hatia","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.gastro.2026.06.019_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/00365521.2023.2277663","article-title":"Clinical characteristics and prognosis of early-onset cholangiocarcinoma: a population-based study","volume":"59","author":"Gao","year":"2024","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.06.019_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2023.101320","article-title":"The global burden of early-onset biliary tract cancer: insight from the Global Burden of Disease Study 2019","volume":"14","author":"Danpanichkul","year":"2024","journal-title":"J Clin Exp Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/HEP.0000000000000970","article-title":"Utility of methylated DNA markers for the diagnosis of malignant biliary strictures","volume":"81","author":"Cooley","year":"2025","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.06.019_bib20","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib21","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Darwish Murad","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.06.019_bib23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/SLA.0000000000005641","article-title":"Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? Results from an international benchmark study","volume":"276","author":"Breuer","year":"2022","journal-title":"Ann Surg"},{"key":"10.1053\/j.gastro.2026.06.019_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hep.32258","article-title":"Liver transplantation for intrahepatic cholangiocarcinoma: ready for prime time?","volume":"75","author":"Sapisochin","year":"2022","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.06.019_bib25","first-page":"815","article-title":"The 2024 ILTS-ILCA consensus recommendations for liver transplantation for hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"31","author":"Kodali","year":"2025","journal-title":"Liver Transpl"},{"key":"10.1053\/j.gastro.2026.06.019_bib26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1186\/s12885-024-12279-6","article-title":"Insights for clinical management from the real-life data of the centralized West of Scotland biliary cancer clinic","volume":"24","author":"Zanuso","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1053\/j.gastro.2026.06.019_bib27","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1053\/j.gastro.2026.06.019_bib28","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib29","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2026.06.019_bib30","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1200\/JCO.2024.42.16_suppl.4093","article-title":"Three-year follow-up data from KEYNOTE-966: pembrolizumab (pembro) plus gemcitabine and cisplatin (gem\/cis) compared with gem\/cis alone for patients (pts) with advanced biliary tract cancer (BTC)","volume":"42","author":"Finn","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib31","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.gastro.2026.06.019_bib33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13073-021-00969-w","article-title":"Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naive study","volume":"13","author":"Sicklick","year":"2021","journal-title":"Genome Med"},{"key":"10.1053\/j.gastro.2026.06.019_bib34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"10.1053\/j.gastro.2026.06.019_bib35","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1200\/JCO.21.02576","article-title":"Precision medicine in biliary tract cancer","volume":"40","author":"Scott","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib36","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib37","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.06.019_bib39","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/his.70116","article-title":"Changes in the 6th edition of the World Health Organization classification of tumours of the digestive system","volume":"88","author":"Arends","year":"2026","journal-title":"Histopathology"},{"key":"10.1053\/j.gastro.2026.06.019_bib40","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.molmed.2025.01.008","article-title":"Molecular subtypes of intrahepatic cholangiocarcinoma","volume":"31","author":"De Santis","year":"2025","journal-title":"Trends Mol Med"},{"key":"10.1053\/j.gastro.2026.06.019_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1214977","article-title":"Extracellular volume fraction using contrast-enhanced CT is useful in differentiating intrahepatic cholangiocellular carcinoma from hepatocellular carcinoma","volume":"13","author":"Honda","year":"2023","journal-title":"Front Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib42","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.acra.2017.06.005","article-title":"Differentiation of intrahepatic cholangiocellular carcinoma from hepatocellular carcinoma in the cirrhotic liver using contrast-enhanced MR imaging","volume":"24","author":"Wengert","year":"2017","journal-title":"Acad Radiol"},{"key":"10.1053\/j.gastro.2026.06.019_bib43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1053\/j.gastro.2026.06.019_bib44","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1158\/1078-0432.CCR-22-0041","article-title":"Transcriptomic profiling of MSI-H\/dMMR gastrointestinal tumors to identify determinants of responsiveness to anti-PD-1 therapy","volume":"28","author":"Chida","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2026.06.019_bib45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","year":"2020","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2026.06.019_bib46","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1053\/j.gastro.2026.06.019_bib48","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/hep.32424","article-title":"Biology of IDH mutant cholangiocarcinoma","volume":"75","author":"Wu","year":"2022","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.06.019_bib49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41575-022-00587-w","article-title":"Mutational signatures and processes in hepatobiliary cancers","volume":"19","author":"Zhuravleva","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib50","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/hep.29764","article-title":"Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma","volume":"68","author":"Nepal","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.06.019_bib51","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2026.06.019_bib52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1053\/j.gastro.2026.06.019_bib53","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib54","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1053\/j.gastro.2022.05.007","article-title":"NOTCH-YAP1\/TEAD-DNMT1 axis drives hepatocyte reprogramming into intrahepatic cholangiocarcinoma","volume":"163","author":"Hu","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.06.019_bib55","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1053\/j.gastro.2024.05.033","article-title":"Human hepatocytes can give rise to intrahepatic cholangiocarcinomas","volume":"167","author":"Hsu","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.06.019_bib56","article-title":"Cell-type specificity of the human mutation landscape with respect to DNA replication dynamics","volume":"3","author":"Caballero","year":"2023","journal-title":"Cell Genom"},{"key":"10.1053\/j.gastro.2026.06.019_bib57","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib58","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1158\/2159-8290.CD-24-1383","article-title":"Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targets","volume":"15","author":"Vijay","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2026.06.019_bib59","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/HEP.0000000000000688","article-title":"Immunogenomics of cholangiocarcinoma","volume":"82","author":"Gehl","year":"2025","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.06.019_bib60","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2022.04.038","article-title":"Metabolic reprogramming in cholangiocarcinoma","volume":"77","author":"Raggi","year":"2022","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib61","article-title":"Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures","volume":"6","author":"Mody","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib62","article-title":"Comprehensive immunogenomic profiling of IDH1-\/2-altered cholangiocarcinoma","volume":"8","author":"Makawita","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib63","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2026.06.019_bib64","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.06.019_bib65","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/gutjnl-2020-322983","article-title":"Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis","volume":"71","author":"Goeppert","year":"2022","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.06.019_bib66","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature13441","article-title":"Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer","volume":"513","author":"Saha","year":"2014","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2026.06.019_bib67","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-21-1077","article-title":"Mutant IDH inhibits IFNgamma-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2026.06.019_bib68","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","article-title":"Mutant p53 suppresses innate immune signaling to promote tumorigenesis","volume":"39","author":"Ghosh","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1053\/j.gastro.2026.06.019_bib69","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/2159-8290.CD-19-0297","article-title":"Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer cells utilizes cytokines from the tumor microenvironment","volume":"10","author":"Dey","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2026.06.019_bib70","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1245\/s10434-024-15013-5","article-title":"Early onset intrahepatic cholangiocarcinoma: clinical characteristics, oncological outcomes, and genomic\/transcriptomic features","volume":"31","author":"Tsilimigras","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib71","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3389\/fonc.2019.01439","article-title":"Genomic features and clinical characteristics of adolescents and young adults with cholangiocarcinoma","volume":"9","author":"Feng","year":"2019","journal-title":"Front Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib72","article-title":"The Cholangiocarcinoma in the Young (CITY) Study: tumor biology, treatment patterns, and survival outcomes in adolescent young adults with cholangiocarcinoma","volume":"7","author":"Pappas","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib73","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jhep.2022.09.025","article-title":"Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer","volume":"78","author":"Okawa","year":"2023","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib74","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/cncr.32740","article-title":"Germline alterations in patients with biliary tract cancers: a spectrum of significant and previously underappreciated findings","volume":"126","author":"Maynard","year":"2020","journal-title":"Cancer"},{"key":"10.1053\/j.gastro.2026.06.019_bib75","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0476","article-title":"Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants","volume":"8","author":"Momozawa","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib76","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1158\/1078-0432.CCR-19-0127","article-title":"Alterations in DNA damage repair genes in primary liver cancer","volume":"25","author":"Lin","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2026.06.019_bib77","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/jnci\/djs351","article-title":"Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome","volume":"104","author":"Win","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.gastro.2026.06.019_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1123901","article-title":"Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: a retrospective analysis from the Finnish National Lynch Syndrome Research Registry","volume":"13","author":"Zalevskaja","year":"2023","journal-title":"Front Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-13569-4","article-title":"Germline variants of ATG7 in familial cholangiocarcinoma alter autophagy and p62","volume":"12","author":"Greer","year":"2022","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2026.06.019_bib80","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"10.1053\/j.gastro.2026.06.019_bib81","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/hep.30493","article-title":"Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma","volume":"69","author":"Goeppert","year":"2019","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.06.019_bib82","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/gutjnl-2023-330483","article-title":"Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies","volume":"73","author":"Hong","year":"2024","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.06.019_bib83","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1158\/0008-5472.CAN-23-3298","article-title":"Whole-genome DNA methylation profiling of intrahepatic cholangiocarcinoma reveals prognostic subtypes with distinct biological drivers","volume":"84","author":"Liao","year":"2024","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2026.06.019_bib84","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jhep.2017.02.017","article-title":"SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma","volume":"67","author":"Merino-Azpitarte","year":"2017","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib85","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/hep.31561","article-title":"DNA methylation of cannabinoid receptor interacting protein 1 promotes pathogenesis of intrahepatic cholangiocarcinoma through suppressing parkin-dependent pyruvate kinase M2 ubiquitination","volume":"73","author":"Chen","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.06.019_bib86","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2019.11.021","article-title":"MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR\/PI3K\/AKT pathways","volume":"72","author":"Tiemin","year":"2020","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib87","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2026.06.019_bib88","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.ccell.2023.07.013","article-title":"Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin","volume":"41","author":"Liang","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1053\/j.gastro.2026.06.019_bib89","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.onc.1210648","article-title":"Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes","volume":"27","author":"Meng","year":"2008","journal-title":"Oncogene"},{"key":"10.1053\/j.gastro.2026.06.019_bib90","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/hep.27823","article-title":"Global DNA methylation and hydroxymethylation differ in hepatocellular carcinoma and cholangiocarcinoma and relate to survival rate","volume":"62","author":"Udali","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.06.019_bib91","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/s43587-023-00462-6","article-title":"Universal DNA methylation age across mammalian tissues","volume":"3","author":"Lu","year":"2023","journal-title":"Nat Aging"},{"key":"10.1053\/j.gastro.2026.06.019_bib92","doi-asserted-by":"crossref","first-page":"9555","DOI":"10.1073\/pnas.1400604111","article-title":"HBx induces hypomethylation of distal intragenic CpG islands required for active expression of developmental regulators","volume":"111","author":"Lee","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2026.06.019_bib93","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/oby.22667","article-title":"Association of hepatic global DNA methylation and serum one-carbon metabolites with histological severity in patients with NAFLD","volume":"28","author":"Lai","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2026.06.019_bib94","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ccr.2014.01.003","article-title":"UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma","volume":"25","author":"Mudbhary","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1053\/j.gastro.2026.06.019_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167534","article-title":"The RFC1 80G>A, among common one-carbon polymorphisms, relates to survival rate according to DNA global methylation in primary liver cancers","volume":"11","author":"Moruzzi","year":"2016","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2026.06.019_bib96","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s12072-019-09954-3","article-title":"Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach","volume":"13","author":"Ahn","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1053\/j.gastro.2026.06.019_bib97","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","year":"2017","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2026.06.019_bib98","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdv483","article-title":"Prognostic factors for progression-free and overall survival in advanced biliary tract cancer","volume":"27","author":"Bridgewater","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib99","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/annonc\/mdv253","article-title":"Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies","volume":"26","author":"Grenader","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2019.05.030","article-title":"score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy","volume":"117","author":"Salati","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.gastro.2026.06.019_bib101","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/gutjnl-2023-330748","article-title":"Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy","volume":"73","author":"O'Rourke","year":"2024","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.06.019_bib102","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.immuni.2024.04.019","article-title":"Classical monocyte ontogeny dictates their functions and fates as tissue macrophages","volume":"57","author":"Trzebanski","year":"2024","journal-title":"Immunity"},{"key":"10.1053\/j.gastro.2026.06.019_bib103","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1172\/JCI137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1053\/j.gastro.2026.06.019_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111384","article-title":"Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis","volume":"40","author":"Keenan","year":"2022","journal-title":"Cell Rep"},{"key":"10.1053\/j.gastro.2026.06.019_bib105","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41586-024-08257-4","article-title":"Cancer cells impair monocyte-mediated T cell stimulation to evade immunity","volume":"637","author":"Elewaut","year":"2025","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2026.06.019_bib106","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.cgh.2019.07.011","article-title":"AGA Clinical Practice Update on surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis: expert review","volume":"17","author":"Bowlus","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib107","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.06.019_bib108","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.pan.2018.09.004","article-title":"Dilemma of elevated CA 19-9 in biliary pathology","volume":"18","author":"Tsen","year":"2018","journal-title":"Pancreatology"},{"key":"10.1053\/j.gastro.2026.06.019_bib109","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/hep4.1730","article-title":"DNA methylation markers for detection of cholangiocarcinoma: discovery, validation, and clinical testing in biliary brushings and plasma","volume":"5","author":"Yang","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2026.06.019_bib110","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib111","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1053\/j.gastro.2015.08.046","article-title":"An optimized set of fluorescence in situ hybridization probes for detection of pancreatobiliary tract cancer in cytology brush samples","volume":"149","author":"Barr Fritcher","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.06.019_bib112","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-21-2384","article-title":"ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma","volume":"28","author":"Verdaguer","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2026.06.019_bib113","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","article-title":"Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications","volume":"72","author":"Martin-Serrano","year":"2023","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.06.019_bib114","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1053\/j.gastro.2023.02.045","article-title":"Refining classification of cholangiocarcinoma subtypes via proteogenomic integration reveals new therapeutic prospects","volume":"164","author":"Cho","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.06.019_bib115","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jhep.2021.06.028","article-title":"Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"75","author":"Ma","year":"2021","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib116","article-title":"Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma","volume":"5","author":"Zhu","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1053\/j.gastro.2026.06.019_bib117","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","article-title":"Spatially confined sub-tumor microenvironments in pancreatic cancer","volume":"184","author":"Grunwald","year":"2021","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2026.06.019_bib118","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1038\/s41588-025-02236-9","article-title":"Multi-omic analysis of gallbladder cancer identifies distinct tumor microenvironments associated with disease progression","volume":"57","author":"Zhou","year":"2025","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2026.06.019_bib119","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/HEP.0000000000001425","article-title":"Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: the ENSCCA registries' framework for digital twin advancement","volume":"83","author":"Carpino","year":"2026","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.06.019_bib120","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.1038\/s41467-023-43749-3","article-title":"Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma","volume":"14","author":"Calderaro","year":"2023","journal-title":"Nat Commun"},{"key":"10.1053\/j.gastro.2026.06.019_bib121","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3390\/jcm9092854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J Clin Med"},{"key":"10.1053\/j.gastro.2026.06.019_bib122","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2024.10.043","article-title":"Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma","volume":"82","author":"Yoo","year":"2025","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib123","article-title":"Detecting early recurrence with circulating tumor DNA in stage I-III Biliary tract cancer after curative resection","volume":"9","author":"Yu","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib124","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","article-title":"Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer","volume":"82","author":"Hwang","year":"2025","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib125","article-title":"Cell-free tumor DNA dominant clone allele frequency is associated with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy","volume":"6","author":"Uson","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib126","article-title":"Monitoring of dynamic changes and clonal evolution in circulating tumor DNA from patients with IDH-mutated cholangiocarcinoma treated with isocitrate dehydrogenase inhibitors","volume":"6","author":"Lapin","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib127","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2026.06.019_bib128","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-23-3780","article-title":"Clinical value of liquid biopsy in patients with FGFR2 fusion-positive cholangiocarcinoma during targeted therapy","volume":"30","author":"Gonzalez-Medina","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2026.06.019_bib129","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.11.017","article-title":"Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib130","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41416-020-01243-3","article-title":"Correction: current and novel therapeutic opportunities for systemic therapy in biliary cancer","volume":"125","author":"Marin","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1053\/j.gastro.2026.06.019_bib131","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2026.06.019_bib132","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib133","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1038\/s41467-022-32436-4","article-title":"Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors","volume":"13","author":"Reinbold","year":"2022","journal-title":"Nat Commun"},{"key":"10.1053\/j.gastro.2026.06.019_bib134","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl6173","article-title":"Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity","volume":"385","author":"Wu","year":"2024","journal-title":"Science"},{"key":"10.1053\/j.gastro.2026.06.019_bib135","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2026.06.019_bib136","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib137","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2026.06.019_bib138","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib139","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib140","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1093\/oncolo\/oyad338","article-title":"First-in-human phase I study of tinengotinib (TT-00420), a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors","volume":"29","author":"Piha-Paul","year":"2024","journal-title":"Oncologist"},{"key":"10.1053\/j.gastro.2026.06.019_bib141","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2024.12.011","article-title":"A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib142","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS575","article-title":"First-308: phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor-refractory\/relapsed cholangiocarcinoma","volume":"42","author":"Javle","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib143","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.434","article-title":"Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: results from phase II clinical trial","volume":"42","author":"Javle","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib144","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2026.06.019_bib145","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2026.06.019_bib146","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2026.06.019_bib147","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.2022.40.16_suppl.3104","article-title":"Mechanisms of acquired resistance to TRK inhibitors","volume":"40","author":"Harada","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1053\/j.gastro.2026.06.019_bib148","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","article-title":"Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK plus) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib149","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib150","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamaoncol.2025.4736","article-title":"Zanidatamab in HER2-positive metastatic biliary tract cancer: final results from HERIZON-BTC-01","volume":"12","author":"Pant","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib151","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib152","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jhep.2022.01.012","article-title":"Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers","volume":"76","author":"Casolino","year":"2022","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.06.019_bib153","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1053\/j.gastro.2026.06.019_bib154","article-title":"Safety and efficacy of anti-human epidermal growth factor 2 agents in the treatment of biliary tract cancers: a systematic review","volume":"9","author":"Naleid","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib155","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.625","article-title":"Analysis of clinically actionable alterations in baseline tumor versus plasma samples in participants of the TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"43","author":"Oh","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib156","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4187","article-title":"GEMINI-Hepatobiliary: a phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers","volume":"42","author":"Zhou","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib157","article-title":"First-line rilvegostomig (rilve) plus chemotherapy (CTx) in advanced biliary tract cancer (BTC): primary analysis of GEMINI-Hepatobiliary substudy 2 Cohort A","volume":"43","author":"Zhou","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib158","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/JCO.2024.42.3_suppl.516","article-title":"PROOF 301: results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion\/rearrangement","volume":"42","author":"Abou-Alfa","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib159","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Bekaii-Saab","year":"2020","journal-title":"Future Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib160","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS648","article-title":"HERIZON-BTC-302: a phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced\/metastatic biliary tract cancer (BTC)","volume":"43","author":"Harding","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib161","volume":"35","author":"Ikeda","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib162","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4219","article-title":"A phase 1b\/2, safety lead-in and dose-expansion trial of ivosidenib plus durvalumab and gemcitabine\/cisplatin as first-line therapy in patients with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation","volume":"43","author":"Harding","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib163","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib164","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12885-015-1498-0","article-title":"Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial","volume":"15","author":"Stein","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1053\/j.gastro.2026.06.019_bib165","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2025-001892","article-title":"Adebrelimab plus capecitabine versus capecitabine monotherapy for adjuvant treatment of high-risk resected cholangiocarcinoma (ACHIEVE): protocol for a phase II, multicentre, randomised controlled trial","volume":"12","author":"Cheng","year":"2025","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1053\/j.gastro.2026.06.019_bib166","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2017.09.005","article-title":"Characterisation of the immune-related transcriptome in resected biliary tract cancers","volume":"86","author":"Ghidini","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.gastro.2026.06.019_bib167","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.4008","article-title":"Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: final results from the phase III AIO\/CALGP\/ACO-GAIN-trial","volume":"43","author":"Goetze","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.06.019_bib168","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"10.1053\/j.gastro.2026.06.019_bib169","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","article-title":"Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial","volume":"31","author":"Lowery","year":"2025","journal-title":"Nat Med"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650852607040X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650852607040X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:34:26Z","timestamp":1792661666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001650852607040X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":168,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S001650852607040X"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2026.06.019","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Subtypes of Cholangiocarcinoma and Their Translational Implications","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2026.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Gastroenterological Association Institute. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}